NA透析器再処理装置市場 - 2030年までの産業動向と予測NA Dialyzer Reprocessing Machines Market - Industry Trends and Forecast to 2030 北米のダイアライザー再処理機市場は、2022年の412億2863万米ドルから2030年には543億9656万米ドルに達し、2023年から2033年の予測期間中に年平均成長率3.5%で成長すると予測される。 市場区分 北米の透析器... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー北米のダイアライザー再処理機市場は、2022年の412億2863万米ドルから2030年には543億9656万米ドルに達し、2023年から2033年の予測期間中に年平均成長率3.5%で成長すると予測される。市場区分 北米の透析器再処理装置市場:タイプ別(自動、半自動)、モダリティ別(ベンチトップ、スタンドアロン)、ステーションタイプ別(シングルステーション、デュアルステーション)、エンドユーザー別(病院、透析センター、ホームユース)、国別(米国、カナダ、メキシコ)-産業動向と2030年までの予測 北米の透析器再処理装置市場ダイナミクスの概要 促進要因 - 末期腎不全(ESRD)の増加 抑制要因 - 厳しい承認規制 機会 - 技術の進歩 市場プレイヤー 北米のダイアライザー再処理機市場で事業を展開している主な市場プレーヤーは以下の通りである: - Geryfalcon Healthcare Pvt. - ザウバーン - ウェスレー・バイオテック - P.K.サイエンティフィック&ケミカルズ - クリニバヘルスケア - アトランティック・バイオメディカル - アドビンヘルスケア - MEDIVATORS社(STERIS社子会社) - その他 目次TABLE OF CONTENTS1 INTRODUCTION 25 1.1 OBJECTIVES OF THE STUDY 25 1.2 MARKET DEFINITION 25 1.3 OVERVIEW OF THE NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET 25 1.4 LIMITATIONS 26 1.5 MARKETS COVERED 27 2 MARKET SEGMENTATION 29 2.1 MARKETS COVERED 29 2.2 GEOGRAPHICAL SCOPE 30 2.3 YEARS CONSIDERED FOR THE STUDY 31 2.4 CURRENCY AND PRICING 31 2.5 DBMR TRIPOD DATA VALIDATION MODEL 32 2.6 MULTIVARIATE MODELLING 35 2.7 TYPE LIFELINE CURVE 35 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36 2.9 DBMR MARKET POSITION GRID 37 2.10 MARKET END USER COVERAGE GRID 38 2.11 VENDOR SHARE ANALYSIS 39 2.12 SECONDARY SOURCES 40 2.13 ASSUMPTIONS 40 3 EXECUTIVE SUMMARY 41 4 PREMIUM INSIGHTS 44 4.1 PESTEL ANALYSIS 45 4.2 PORTER’S FIVE FORCES MODEL 46 4.3 STRATEGIC INITIATIVES 47 5 NORTH AMERICA DIALYZER PROCESSING MACHINES MARKET, REGULATIONS 48 5.1 REGULATORY SCENARIO IN THE U.S 48 6 MARKET OVERVIEW 49 6.1 DRIVERS 51 6.1.1 INCREASING PREVALENCE OF END-STAGE RENAL DISEASE (ESRD) 51 6.1.2 RISING DEMAND FOR HOME-BASED DIALYSIS PROCEDURES 51 6.1.3 COST-EFFECTIVENESS AND EFFICIENCY 52 6.2 RESTRAINTS 53 6.2.1 STRINGENT REGULATIONS FOR APPROVAL 53 6.2.2 POSSIBLE RISK OF INFECTIONS 53 6.3 OPPORTUNITIES 54 6.3.1 RISE IN TECHNOLOGICAL ADVANCEMENTS 54 6.3.2 INCREASING FOCUS ON INFECTION CONTROL 55 6.4 CHALLENGES 55 6.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS TO OPERATE DIALYZER REPROCESSING MACHINES 55 6.4.2 LACK OF STANDARDIZATION 56 7 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET, BY TYPE 57 7.1 OVERVIEW 58 7.2 SEMI-AUTOMATIC 61 7.3 AUTOMATIC 62 8 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET, BY MODALITY 63 8.1 OVERVIEW 64 8.2 BENCHTOP 67 8.2.1 SEMI-AUTOMATIC 68 8.2.2 AUTOMATIC 68 8.3 STANDALONE 68 8.3.1 SEMI-AUTOMATIC 69 8.3.2 AUTOMATIC 69 9 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET, BY STATION TYPE 70 9.1 OVERVIEW 71 9.2 DUAL STATION 74 9.3 SINGLE STATION 75 10 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET, BY END USER 76 10.1 OVERVIEW 77 10.2 DIALYSIS CENTERS 80 10.3 HOSPITAL 81 10.4 HOME USE 82 11 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET, BY REGION 83 11.1 NORTH AMERICA 84 11.1.1 U.S. 91 11.1.2 CANADA 93 11.1.3 MEXICO 95 12 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET: COMPANY LANDSCAPE 97 12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 97 13 SWOT ANALYSIS 98 14 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET 99 14.1 MEDIVATORS INC. (SUBSIDIARY OF STERIS) 99 14.1.1 COMPANY SNAPSHOT 99 14.1.2 REVENUE ANALYSIS 99 14.1.3 COMPANY SHARE ANALYSIS 100 14.1.4 PRODUCT PORTFOLIO 100 14.1.5 RECENT DEVELOPMENTS 100 14.2 HEMANT SURGICAL INDUSTRIES LTD. 101 14.2.1 COMPANY SNAPSHOT 101 14.2.2 REVENUE ANALYSIS 101 14.2.3 COMPANY SHARE ANALYSIS 102 14.2.4 PRODUCT PORTFOLIO 102 14.2.5 RECENT DEVELOPMENTS 102 14.3 SAUBERN 103 14.3.1 COMPANY SNAPSHOT 103 14.3.2 COMPANY SHARE ANALYSIS 103 14.3.3 PRODUCT PORTFOLIO 104 14.3.4 RECENT DEVELOPMENTS 104 14.4 P.K. SCIENTIFIC & CHEMICALS 105 14.4.1 COMPANY SNAPSHOT 105 14.4.2 PRODUCT PORTFOLIO 105 14.4.3 RECENT DEVELOPMENT 105 14.5 LABSMED. 106 14.5.1 COMPANY SNAPSHOT 106 14.5.2 COMPANY SHARE ANALYSIS 106 14.5.3 PRODUCT PORTFOLIO 107 14.5.4 RECENT DEVELOPMENTS 107 14.6 ATLANTIC BIOMEDICAL 108 14.6.1 COMPANY SNAPSHOT 108 14.6.2 COMAPYN SHARE ANALYSIS 108 14.6.3 PRODUCT PORTFOLIO 109 14.6.4 RECENT DEVELOPMENT 109 14.7 ADVIN HEALTH CARE 110 14.7.1 COMPANY SNAPSHOT 110 14.7.2 PRODUCT PORTFOLIO 110 14.7.3 RECENT DEVELOPMENTS 110 14.8 ANJUE MEDICAL EQUIPMENT CO., LTD. 111 14.8.1 COMPANY SNAPSHOT 111 14.8.2 PRODUCT PORTFOLIO 111 14.8.3 RECENT DEVELOPMENT 111 14.9 CLINIVA HEALTHCARE 112 14.9.1 COMPANY SNAPSHOT 112 14.9.2 PRODUCT PORTFOLIO 112 14.9.3 RECENT DEVELOPMENT 112 14.10 GERYFALCON HEALTHCARE PVT. LTD. 113 14.10.1 COMPANY SNAPSHOT 113 14.10.2 PRODUCT PORTFOLIO 113 14.10.3 RECENT DEVELOPMENT 113 14.11 NANOTECH 114 14.11.1 COMPANY SNAPSHOT 114 14.11.2 PRODUCT PORTFOLIO 114 14.11.3 RECENT DEVELOPMENTS 114 14.12 WESLEY BIOTECH 115 14.12.1 COMPANY SNAPSHOT 115 14.12.2 PRODUCT PORTFOLIO 115 14.12.3 RECENT DEVELOPMENT 115 15 QUESTIONNAIRE 116 16 RELATED REPORTS 119
SummaryNorth America dialyzer reprocessing machines market is expected to reach USD 54,396.56 million by 2030 from USD 41,228.63 million in 2022, growing at a CAGR of 3.5% during the forecast period of 2023 to 2033. Table of ContentsTABLE OF CONTENTS1 INTRODUCTION 25 1.1 OBJECTIVES OF THE STUDY 25 1.2 MARKET DEFINITION 25 1.3 OVERVIEW OF THE NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET 25 1.4 LIMITATIONS 26 1.5 MARKETS COVERED 27 2 MARKET SEGMENTATION 29 2.1 MARKETS COVERED 29 2.2 GEOGRAPHICAL SCOPE 30 2.3 YEARS CONSIDERED FOR THE STUDY 31 2.4 CURRENCY AND PRICING 31 2.5 DBMR TRIPOD DATA VALIDATION MODEL 32 2.6 MULTIVARIATE MODELLING 35 2.7 TYPE LIFELINE CURVE 35 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36 2.9 DBMR MARKET POSITION GRID 37 2.10 MARKET END USER COVERAGE GRID 38 2.11 VENDOR SHARE ANALYSIS 39 2.12 SECONDARY SOURCES 40 2.13 ASSUMPTIONS 40 3 EXECUTIVE SUMMARY 41 4 PREMIUM INSIGHTS 44 4.1 PESTEL ANALYSIS 45 4.2 PORTER’S FIVE FORCES MODEL 46 4.3 STRATEGIC INITIATIVES 47 5 NORTH AMERICA DIALYZER PROCESSING MACHINES MARKET, REGULATIONS 48 5.1 REGULATORY SCENARIO IN THE U.S 48 6 MARKET OVERVIEW 49 6.1 DRIVERS 51 6.1.1 INCREASING PREVALENCE OF END-STAGE RENAL DISEASE (ESRD) 51 6.1.2 RISING DEMAND FOR HOME-BASED DIALYSIS PROCEDURES 51 6.1.3 COST-EFFECTIVENESS AND EFFICIENCY 52 6.2 RESTRAINTS 53 6.2.1 STRINGENT REGULATIONS FOR APPROVAL 53 6.2.2 POSSIBLE RISK OF INFECTIONS 53 6.3 OPPORTUNITIES 54 6.3.1 RISE IN TECHNOLOGICAL ADVANCEMENTS 54 6.3.2 INCREASING FOCUS ON INFECTION CONTROL 55 6.4 CHALLENGES 55 6.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS TO OPERATE DIALYZER REPROCESSING MACHINES 55 6.4.2 LACK OF STANDARDIZATION 56 7 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET, BY TYPE 57 7.1 OVERVIEW 58 7.2 SEMI-AUTOMATIC 61 7.3 AUTOMATIC 62 8 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET, BY MODALITY 63 8.1 OVERVIEW 64 8.2 BENCHTOP 67 8.2.1 SEMI-AUTOMATIC 68 8.2.2 AUTOMATIC 68 8.3 STANDALONE 68 8.3.1 SEMI-AUTOMATIC 69 8.3.2 AUTOMATIC 69 9 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET, BY STATION TYPE 70 9.1 OVERVIEW 71 9.2 DUAL STATION 74 9.3 SINGLE STATION 75 10 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET, BY END USER 76 10.1 OVERVIEW 77 10.2 DIALYSIS CENTERS 80 10.3 HOSPITAL 81 10.4 HOME USE 82 11 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET, BY REGION 83 11.1 NORTH AMERICA 84 11.1.1 U.S. 91 11.1.2 CANADA 93 11.1.3 MEXICO 95 12 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET: COMPANY LANDSCAPE 97 12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 97 13 SWOT ANALYSIS 98 14 NORTH AMERICA DIALYZER REPROCESSING MACHINES MARKET 99 14.1 MEDIVATORS INC. (SUBSIDIARY OF STERIS) 99 14.1.1 COMPANY SNAPSHOT 99 14.1.2 REVENUE ANALYSIS 99 14.1.3 COMPANY SHARE ANALYSIS 100 14.1.4 PRODUCT PORTFOLIO 100 14.1.5 RECENT DEVELOPMENTS 100 14.2 HEMANT SURGICAL INDUSTRIES LTD. 101 14.2.1 COMPANY SNAPSHOT 101 14.2.2 REVENUE ANALYSIS 101 14.2.3 COMPANY SHARE ANALYSIS 102 14.2.4 PRODUCT PORTFOLIO 102 14.2.5 RECENT DEVELOPMENTS 102 14.3 SAUBERN 103 14.3.1 COMPANY SNAPSHOT 103 14.3.2 COMPANY SHARE ANALYSIS 103 14.3.3 PRODUCT PORTFOLIO 104 14.3.4 RECENT DEVELOPMENTS 104 14.4 P.K. SCIENTIFIC & CHEMICALS 105 14.4.1 COMPANY SNAPSHOT 105 14.4.2 PRODUCT PORTFOLIO 105 14.4.3 RECENT DEVELOPMENT 105 14.5 LABSMED. 106 14.5.1 COMPANY SNAPSHOT 106 14.5.2 COMPANY SHARE ANALYSIS 106 14.5.3 PRODUCT PORTFOLIO 107 14.5.4 RECENT DEVELOPMENTS 107 14.6 ATLANTIC BIOMEDICAL 108 14.6.1 COMPANY SNAPSHOT 108 14.6.2 COMAPYN SHARE ANALYSIS 108 14.6.3 PRODUCT PORTFOLIO 109 14.6.4 RECENT DEVELOPMENT 109 14.7 ADVIN HEALTH CARE 110 14.7.1 COMPANY SNAPSHOT 110 14.7.2 PRODUCT PORTFOLIO 110 14.7.3 RECENT DEVELOPMENTS 110 14.8 ANJUE MEDICAL EQUIPMENT CO., LTD. 111 14.8.1 COMPANY SNAPSHOT 111 14.8.2 PRODUCT PORTFOLIO 111 14.8.3 RECENT DEVELOPMENT 111 14.9 CLINIVA HEALTHCARE 112 14.9.1 COMPANY SNAPSHOT 112 14.9.2 PRODUCT PORTFOLIO 112 14.9.3 RECENT DEVELOPMENT 112 14.10 GERYFALCON HEALTHCARE PVT. LTD. 113 14.10.1 COMPANY SNAPSHOT 113 14.10.2 PRODUCT PORTFOLIO 113 14.10.3 RECENT DEVELOPMENT 113 14.11 NANOTECH 114 14.11.1 COMPANY SNAPSHOT 114 14.11.2 PRODUCT PORTFOLIO 114 14.11.3 RECENT DEVELOPMENTS 114 14.12 WESLEY BIOTECH 115 14.12.1 COMPANY SNAPSHOT 115 14.12.2 PRODUCT PORTFOLIO 115 14.12.3 RECENT DEVELOPMENT 115 15 QUESTIONNAIRE 116 16 RELATED REPORTS 119
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
Data Bridge Market Research社の医療デバイス分野での最新刊レポート
本レポートと同じKEY WORD(industry)の最新刊レポート
よくあるご質問Data Bridge Market Research社はどのような調査会社ですか?データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/18 10:27 154.74 円 162.88 円 199.42 円 |